Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 6/20 | 0.47 |
| ▸ | CD274 | Q9NZQ7 | 6/20 | 0.47 |
| ▸ | MAP3K5 | Q99683 | 8/20 | 0.46 |
| ▸ | PRMT5 | O14744 | 5/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 5/20 | 0.39 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30389787 | 1.00 | PDCD1 (0.47) | PDCD1CD274MAP3K5PRMT5WDR77 | |
| SCHEMBL24127439 | 1.00 | PDCD1 (0.47) | PDCD1CD274MAP3K5PRMT5WDR77 | |
| SCHEMBL30595963 | 0.90 | MAP3K5 (0.43) | PDCD1CD274MAP3K5PRMT5WDR77 | |
| SCHEMBL24127451 | 0.90 | MAP3K5 (0.43) | PDCD1CD274MAP3K5PRMT5WDR77 | |
| SCHEMBL25893900 | 0.90 | MAP3K5 (0.42) | PDCD1CD274MAP3K5PRMT5WDR77 | |
| SCHEMBL24127440 | 0.89 | MAP3K5 (0.47) | PDCD1CD274MAP3K5PRMT5WDR77 | |
| SCHEMBL30596010 | 0.89 | MAP3K5 (0.47) | PDCD1CD274MAP3K5PRMT5WDR77 | |
| SCHEMBL24127327 | 0.87 | MAP3K5 (0.40) | PDCD1CD274MAP3K5PRMT5WDR77 | |
| SCHEMBL30595971 | 0.87 | MAP3K5 (0.40) | PDCD1CD274MAP3K5PRMT5WDR77 | |
| SCHEMBL24127335 | 0.87 | MAP3K5 (0.42) | PDCD1CD274MAP3K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234970-A1 | IMMUNOSUPPRESSANT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
| EP-4174066-A1 | IMMUNOSUPPRESSANT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2023-05-03 | — | — | EP | disclosed |
| EP-4174066-A1 | IMMUNOSUPPRESSANT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2023-05-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234970-A1 | IMMUNOSUPPRESSANT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | CD274, PDCD1, PDCD1LG2 | PDCD1 2/4885CD274 1/4885MAP3K5 341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.